RSV Prevention in Pediatrics
All infants younger than 8 months born during or entering their first RSV season should receive RSV immunization with either nirsevimab or clesrovimab, unless the birthing parent received RSVpreF vaccine ≥14 days before delivery. 1, 2
First RSV Season (Infants <8 Months)
The landscape of RSV prevention has fundamentally shifted from selective prophylaxis to universal infant protection. The 2026 AAP guidelines represent a paradigm change from the restrictive palivizumab era.
Immunization options for first season:
- Nirsevimab (Beyfortus): 50 mg for infants <5 kg; 100 mg for infants ≥5 kg, single IM dose 2
- Clesrovimab: 105 mg for all infants regardless of weight, single IM dose 2
- Maternal RSVpreF vaccine (ABRYSVO): Given to pregnant women at 32-36 weeks gestation 2
Timing of administration (October-March in most US regions):
- Infants born during RSV season: administer within 1 week of birth, ideally during birth hospitalization 2
- Infants born outside RSV season (April-September): administer beginning in October before peak season 2
When NOT to give infant RSV antibody:
- Mother received RSVpreF vaccine ≥14 days before delivery 2
- Exception: If maternal vaccination status is unknown, proceed with infant immunization 1
Second RSV Season (Children 8-19 Months)
RSV immunization is recommended for high-risk children entering their second season, regardless of prior immunization status. 1 This represents a significant expansion from previous guidance.
High-risk criteria (any of the following):
Prematurity: Born <32 weeks, 0 days gestation (no longer requires ongoing medical support) 1
Chronic lung disease: Required medical support (oxygen, corticosteroids, diuretics) during the 6 months before RSV season 1
Hemodynamically significant congenital heart disease: Defects causing symptoms or cardiac chamber dilation 1
Anatomic pulmonary abnormalities or neuromuscular disorders impairing secretion clearance 1
Severe immunocompromise 1
Down syndrome or other chromosomal differences conferring higher RSV risk 1
Cystic fibrosis with:
- Previous hospitalization for pulmonary exacerbation in first year, OR
- Persistent chest imaging abnormalities, OR
- Weight-for-length <10th percentile 1
American Indian or Alaska Native children (due to significantly higher hospitalization rates and social determinants of health) 1
Key Clinical Considerations
Discontinue prophylaxis after breakthrough RSV hospitalization - the likelihood of second hospitalization in same season is <0.5% 3
Post-cardiac bypass dosing: Administer additional 15 mg/kg palivizumab dose after cardiopulmonary bypass (58% mean decrease in serum concentration observed) 3
Maximum doses per season:
- Nirsevimab/clesrovimab: Single dose provides >6 months protection 3
- Palivizumab (if used): Maximum 5 monthly doses 3
Palivizumab is no longer preferred due to superior efficacy, duration, and convenience of nirsevimab and clesrovimab 4
Important Caveats
The 2014 AAP guidance 3 previously restricted prophylaxis to infants <29 weeks gestation, but the 2026 recommendations 1 now support universal first-season protection through either maternal vaccination or infant immunization. This reflects real-world effectiveness data showing 80.9% protection against RSV hospitalization with nirsevimab and 79.1% with maternal RSVpreF 5.
Geographic variations: Alaska and tropical climates may have unpredictable RSV patterns - consult state/territorial health departments for modified timing 2
Palivizumab has NO therapeutic efficacy - it is prophylaxis only and should not be used for treatment of active RSV disease 3
Healthcare-associated RSV: Palivizumab is not recommended for outbreak control; strict infection control practices are the foundation 3